Axel Mark
3624
DREAM VISION
3185
MarketEnterprise
3135
Nippon Denkai
5759
Seed
7743
JP Stock MarketDetailed Quotes
4578 Otsuka Holdings
- 8595.0
- -5.0-0.06%
20min DelayNoon Break Dec 24 11:30 JST
4.74TMarket Cap38.35P/E (Static)
8626.0High8571.0Low183.80KVolume8587.0Open8600.0Pre Close1.58BTurnover9669.052wk High0.05%Turnover Ratio552.02MShares5030.052wk Low279.44EPS TTM3.39TFloat Cap9669.0Historical High38.35P/E (Static)394.68MShs Float1737.0Historical Low224.1EPS LYR0.64%Amplitude120.00Dividend TTM1.85P/B100Lot Size1.40%Div YieldTTM
Otsuka Holdings News
Otsuka Holdings: Notification of Completion of Share Repurchase and Number of Treasury Stock to be Cancelled
Otsuka Holdings: Otsuka Pharmaceutical Plant establishes a joint venture with ICU Medical in the US
Otsuka Holdings: Otsuka Pharmaceutical Factory, Inc. and ICU Medical Announce the Establishment of Joint Venture
Otsuka Holdings: Notice Regarding the Status of Share Repurchases
Otsuka Holdings: Changes of Representative Director
Otsuka Holdings: Consolidated Financial Results for the Nine-Month Period Ended September 30, 2024 [IFRS]
Otsuka Holdings: Otsuka Announces Positive Interim Results from the Phase 3 Trial of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy in Adults
Otsuka Holdings: Good interim analysis results of the phase 3 trial targeting the novel APRIL antibody “sibeprenlimab” IgA nephropathy
Otsuka Holdings: Notice Regarding the Status of Share Repurchases
Otsuka Holdings: Notice Regarding Change in Major Shareholders
Otsuka Holdings: Notice Concerning Changes in Major Shareholders
Otsuka Holdings: Obtaining approval for additional efficacy of the antipsychotic drug “Lexarti” in Japan
Otsuka Holdings: Otsuka Obtains Additional Indication for Rexulti in Japan as an Adjunctive Treatment for Agitation Associated with Dementia due to Alzheimer's Disease
Otsuka Holdings: Notice Regarding the Status of Share Repurchases
Otsuka Holdings: Integrated Report 2024 of Otsuka Holdings Co., Ltd.
Otsuka Holdings: Regarding the acquisition of Jnana Therapeutics by Otsuka Pharmaceutical in the United States.
Otsuka Holdings: Otsuka Pharmaceutical acquired Junana Therapeutics.
Otsuka Holdings: Announcements of individual stock regarding the repurchase of company shares and the cancellation of treasury stocks.
Otsuka Holdings: Consolidated financial results for the six months ended June 30, 2024 [IFRS]
Otsuka Holdings: Announcement of revised financial estimates for the first half of fiscal year 2024